Immunovant (IMVT) EV/FCF: History & Chart

Immunovant, Inc.(IMVT)

Biotechnology · Durham, NY

$32.17-1.08 (-3.25%)

Delayed quote: Oct 6, 2026, 12:10 PM EDT

About Immunovant, Inc.

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Durham, NY

315 employees

immunovant.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Eric Venker

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Immunovant, Inc. (IMVT)	$6.64B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.67B	21.49x	18.31x	25.20x	27.69x
Hims & Hers Health, Inc. (HIMS)vs ›	$6.57B	83.50x	87.18x	71.94x	74.12x
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.53B	110.58x	42.06x	30.94x	38.19x
Lantheus Holdings, Inc. (LNTH)vs ›	$6.51B	16.86x	14.73x	15.32x	29.74x
Rhythm Pharmaceuticals, Inc. (RYTM)vs ›	$6.41B	N/A	N/A	N/A	N/A
Alkermes plc (ALKS)vs ›	$7.04B	36.56x	22.08x	16.34x	41.62x
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.97B	46.37x	89.11x	55.49x	41.54x
GRAIL Inc. (GRAL)vs ›	$5.96B	N/A	N/A	N/A	N/A
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.36B	N/A	178.07x	109.13x	82.68x

NAME

MARKET CAP

EV/FCF RATIO

TTM

Immunovant, Inc. (IMVT)

$6.64B

N/A

Chemed Corporation (CHE)vs ›

$6.67B

21.49x

18.31x

25.20x